Novel approaches and careful experimental design, combined with large-scale, high-throughput methods and cutting-edge analysis pipelines, have to be utilized to delineate the antiviral innate immune landscape at a global level. In this review, we describe different currently used screening approaches, how they contributed to our knowledge on virus–host interactions, and essential considerations that have to be taken into account when planning such experiments.
The review can be found here.
Incucyte S3 live-cell imaging screening paltform
We recently established a screening platform based on an incucyte S3 time-lapse microscopy system to test for antiviral drugs in BSL3 conditions. This allows us medium throughput testing (~72 compounds in 2-3 days) of antiviral compounds.
We are using SARS-CoV-2 GFP just published by our collaborator Volker Thiel, which serves as a great tool to study the influence of drugs in a time-resolved manner.
We want to thank for generous support from the Max-von-Bauernfeind Association and TUM!
10x Genomics - single-cell genomics in BSL-3 conditions
In this collaborative project, Chris and Hendrik found that long-term delivery of RIG-I ligand leads to cytostasis. Surprisingly, unlike found for other innate immune stimuli (e.g. LPS) persistent activation of the RIG-I pathway does not lead to tolerance. We hypothesize that this system recapitulates the situation in HCV-infected livers, which requires constant re-infection of cells in order to persistently propagate the virus. A beautiful story – which you can read here.